AKUMS

** Shares of Akums Drugs and Pharmaceuticals AKUM.NS rise 3.5% to 497 rupees

** Drugmaker posts 5.5% Y/Y rise in June-qtr consol net profit; consol rev from ops rises 0.5% Y/Y

** AKUM rated "strong buy" by 3 analysts on average; median target price is 710 rupees – data compiled by LSEG

** Stock down 22% YTD

(Reporting by Rudra Pratap Singh in Bengaluru)

(([email protected]))

** Shares of Akums Drugs AKUM.NS rise 2.1% to 519 rupees apiece

** Citi Research initiates coverage of the co, which is a contract development and manufacturing organisation (CDMO), with "buy"

** Brokerage sets PT of 700 rupees, implying a 12-month return of 37.8%

** Says AKUM has an edge over competition in terms of scale, manufacturing capabilities

** Adds recent weakness due to correction in the prices of active pharma ingredients (API) will be transient, expects recovery in fiscal 2026 and 2027

** AKUM's 100-million-euro CDMO contract from a global pharma company will aid earnings, showcases potential to make inroads in international markets, says Citi

** AKUM shares down 19% in 2025 so far, nearly twice as much as the 9.5% drop in Nifty 500 index .NIFTY500 - data compiled by LSEG

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

** Akums Drugs and Pharmaceuticals AKUM.NS falls 4.5%, set for biggest one-day drop since Nov 28, 2024

** Co says India's income tax department conducted searches at its offices and manufacturing units of its subsidiaries

** Says operations continuing as usual, with minor hiccups

** Stock set to fall for a third straight session; has slid ~18% since listing on Aug 6, 2024

(Reporting by Anuran Sadhu in Bengaluru)

(([email protected]; +91 8697274436;))

Nov 26 (Reuters) - Akums Drugs and Pharmaceuticals Ltd AKUM.NS:

• AKUMS DRUGS - TIES UP WITH JAGDALE FOR MARKETING READY TO DRINK NUTRITIONAL BEVERAGES

Source text: ID:nBSE2tT0S5

Further company coverage: AKUM.NS

(([email protected];))

** Akum Drugs and Pharmaceuticals AKUM.NS rises to exchange-allowed upper circuit of 5% to 580.7 rupees

** Co enters into agreement with Caregen 214370.KQ, a South Korean firm that makes cosmeceuticals and dermal fillers

** Deal grants Akum exclusive rights to sell certain Caregen products in India

** Stock set to snap 10 sessions of losses

** About 2.3 mln shares traded, 10.4x 30-day avg

** AKUM down 23.7% since listing on Aug. 6, as of last close

(Reporting by Anuran Sadhu in Bengaluru)

(([email protected]; +91 8697274436;))

Oct 16 (Reuters) - Akums Drugs and Pharmaceuticals Ltd AKUM.NS:

• EXECUTION OF LICENSE & DISTRIBUTION AGREEMENT WITH TRIPLE HAIR

Source text for Eikon: ID:nBSE7M3QCt

Further company coverage: AKUM.NS

(([email protected];))

Oct 9 (Reuters) - Akums Drugs and Pharmaceuticals Ltd AKUM.NS:

• LAUNCHES FAMOTIDINE, CALCIUM CARBONATE, MAGNESIUM HYDROXIDE IN INDIA

Source text for Eikon: ID:nNSE5PN7K9

Further company coverage: AKUM.NS

(([email protected];;))